US 12,264,203 B2
Humanized complement 5a receptor 1 antibodies and methods of use thereof
Karthik Viswanathan, Waltham, MA (US); Brian Booth, Waltham, MA (US); Boopathy Ramakrishnan, Waltham, MA (US); Andrew Wollacott, Waltham, MA (US); Gregory Babcock, Waltham, MA (US); Zachary Shriver, Waltham, MA (US); and Lauren Olinski, Waltham, MA (US)
Assigned to Visterra, Inc., Waltham, MA (US)
Filed by VISTERRA, INC., Waltham, MA (US)
Filed on May 31, 2024, as Appl. No. 18/731,146.
Application 18/731,146 is a division of application No. 18/415,419, filed on Jan. 17, 2024.
Application 18/415,419 is a division of application No. 17/575,420, filed on Jan. 13, 2022, granted, now 11,912,781, issued on Feb. 27, 2024.
Claims priority of provisional application 63/274,748, filed on Nov. 2, 2021.
Claims priority of provisional application 63/137,089, filed on Jan. 13, 2021.
Prior Publication US 2024/0392029 A1, Nov. 28, 2024
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 37/02 (2006.01)
CPC C07K 16/2896 (2013.01) [A61P 37/02 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01)] 13 Claims
OG exemplary drawing
 
1. An antibody or antigen binding fragment thereof that binds complement component 5a receptor 1 (C5aR1), comprising a heavy chain variable (VH) region, wherein the VH comprises three heavy chain complementarity determining regions (HCDRs), wherein the HCDR1, HCDR2, and HCDR3 sequences comprising amino acid sequences of SEQ ID Nos: 6, 7, and 8, respectively and a light chain variable (VL) region, wherein the VL comprises three light chain complementarity determining regions (LCDRs), wherein the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID Nos: 9, 10, and 11, respectively.